CompoAtlas

NATURAL KETO COUPE FAIM PLUS

Integratore alimentare dichiarato in Francia, notifica n. 2024-7-485, decisione del 8 luglio 2024

NATURAL KETO COUPE FAIM PLUS, dell'azienda LALFOF SRLS, è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. Ingredienti principali: Opuntia ficus-indica 400 mg al giorno, Garcinia gummi-gutta 400 mg al giorno, Glucomannane. 1 punto della sua composizione richiede una verifica (sostanza vietata, dose o nuovo alimento).

Marca
non indicata
Responsabile dell’immissione in commercio
LALFOF SRLS
Stato
Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)
Forma
Capsula
Dose giornaliera

Testo originale in francese.

4 CPS

Compl’Alim, dichiarazioni di integratori alimentari ·

Modalità d’uso

Testo originale in francese.

Total 4 gélules par jour avec beaucoup d'eau.

Compl’Alim, dichiarazioni di integratori alimentari ·

Sconsigliato (secondo il fabbricante)
Deficit congenito di G6PD (favismo), Bambini (sotto i 12 anni), In trattamento antipertensivo, In trattamento per la tiroide, Uso prolungato, Bambini (sotto i 6 anni), Bambini (sotto i 10 anni)
Obiettivi dichiarati dal fabbricante (non sono indicazioni autorizzate)
Transito intestinale, Detox / Drenaggio, Digestione, Dimagrimento / Bruciagrassi, Dimagrimento / Pancia piatta

Notifica 331800, procedura Article 15. Compl’Alim, dichiarazioni di integratori alimentari, consultato il 15 novembre 2026.

Composizione dichiarata

Piante

PiantaPartePreparazioneAl giorno
Opuntia ficus-indica (L.) Mill.FeuilleAutre extrait sec400 mg
Garcinia gummi-gutta (L.) Roxb.Gomme résineExtrait sec aqueux400 mg

Altri ingredienti attivi

NomeAl giorno
Glucomannanenon dichiarata

Elenco della dichiarazione, decisione dell'amministrazione del (Compl’Alim, dichiarazioni di integratori alimentari).

Fotografare la confezione

Aspetti normativi

Queste informazioni riprendono la dichiarazione del fabbricante all’amministrazione (DGAL). Non dicono se il prodotto sia efficace e non sostituiscono il parere di un medico o farmacista, in particolare in gravidanza o durante un trattamento.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Garcinia gummi-gutta (L.) Roxb.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    MALABAR TAMARIND - GARCINIA GUMMI-GUTTA

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder (HC 2025).

    Fonti citate da Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Garcinia gummi-gutta and Hydroxycitric Acid - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1755272782909
    • SC 2025 : Santé Canada : Résumé de l'examen de l'innocuité - Garcinia gummi-gutta et acide hydroxycitrique - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1755272782909

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Fonti citate da Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Garcinia gummi-gutta and Hydroxycitric Acid - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1755272782909
    • SC 2025 : Santé Canada : Résumé de l'examen de l'innocuité - Garcinia gummi-gutta et acide hydroxycitrique - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1755272782909

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Fonti citate da Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Garcinia gummi-gutta and Hydroxycitric Acid - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1755272782909
    • SC 2025 : Santé Canada : Résumé de l'examen de l'innocuité - Garcinia gummi-gutta et acide hydroxycitrique - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1755272782909

    Controindicazioni

    Condizione di applicazione: All products.

    Do not use if you are pregnant (HC 2010).

    Fonti citate da Health Canada (2)
    • HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
    • SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf

    Monografia di Health Canada del 26 settembre 2025

  • Glucomannane
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    GLUCOMANNAN

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (FDA 2023).

    Fonti citate da Health Canada (1)
    • FDA 2023: United States Food and Drug Administration. Specific Labeling Requirements for Specific Drug Products. Code of Federal Regulations Title 21, Volume 4 (21CFR201.319). Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2023 December 31]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.319

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (UpToDate 2023; EMA 2013; Chen et al. 2003; Vuksan et al. 2001).

    Fonti citate da Health Canada (4)
    • Chen HL, Sheu WH, Tai TS, Liaw YP, Chen YC. 2003. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects—a randomized double-blind trial. Journal of American College of Nutrition 22(1):36-42.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf
    • UpToDate 2023: Wolters Kluwer. [Accessed 2023 December 31]. Available from: https://www.wolterskluwer.com/en/solutions/uptodate
    • Vuksan V, Sievenpiper JL, Xu Z, Wong EYY, Jenkins AL, Beljan-Zdravkovic U, Leiter LA, Josse RG, Stavro M.P. 2001. Konjac-mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. Journal of the American College of Nutrition 20:370S-380S.

    Condizione di applicazione: Laxative; Promotion of bowel movement; Constipation relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    Fonti citate da Health Canada (2)
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
    • Repchinsky C, editor. 2002. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.

    Controindicazioni

    Condizione di applicazione: All products.

    Do not use if you have difficulty swallowing (FDA 2023; Sweetman 2007; Vanderbeek et al. 2007; Henry et al. 1986).

    Fonti citate da Health Canada (5)
    • FDA 2023: United States Food and Drug Administration. Specific Labeling Requirements for Specific Drug Products. Code of Federal Regulations Title 21, Volume 4 (21CFR201.319). Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2023 December 31]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.319
    • Henry DA, Mitchell AS, Aylward J. 1986. Glucomannan and risk of esophageal obstruction. British Medical Journal 292:591-592.
    • Sweetman SC, editor. 2007. Martindale: The Complete Drug Reference, 35th edition. London (GB): Pharmaceutical Press.
    • Vanderbeek PB, Fasano C, O'Malley G, Hornstein J. 2007. Esophageal obstruction from a pharmacobezoar containing glucomannan. Clinical Toxicology 45(1):80-82.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Consulté le 31 décembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2013; Pray 2006; Berardi et al. 2002).

    Fonti citate da Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2013).

    Fonti citate da Health Canada (1)
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf

    When using this product you may experience temporary gas and bloating (Sood et al. 2008).

    Fonti citate da Health Canada (1)
    • Sood N, Baker WL, Coleman CI. 2008. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. American Journal of Clinical Nutrition 88(4):1167-1175.

    Monografia di Health Canada del 26 luglio 2024

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Elenco rilevato nel 2024. Fotografi la confezione per verificare eventuali modifiche.

Invio per analizzare, Maiusc+Invio per una nuova riga